Literature DB >> 14687256

Development and validation of the hyperlipidemia: attitudes and beliefs in treatment (HABIT) survey for physicians.

Kathleen A Foley1, Joseph Vasey, Charles M Alexander, Leona E Markson.   

Abstract

INTRODUCTION: Many patients treated with lipid-lowering medications in clinical practice do not achieve targeted National Cholesterol Education Program (NCEP) goals for low-density lipoprotein cholesterol (LDL-C), despite the proven efficacy of these medications. Understanding physician attitudes and beliefs about treating patients to goal may be useful in improving patient care and ensuring that all patients receive the benefits of treatments shown to be optimal in clinical trials.
OBJECTIVE: To develop a theoretically based, and statistically reliable and valid survey instrument for measuring the attitudes and beliefs of physicians toward hyperlipidemia and its treatment, including treatment of patients to goal. To determine whether the attitudes measured were associated with physician intentions to treat patients to LDL-C goal.
METHODS: We assessed the reliability of the instrument through an examination of the internal consistency and factor structure of the constructs. Validity was assessed through zero-order correlations among the constructs and the relationship between the constructs and an intent to treat to goal case study.
RESULTS: Internal consistency scores for the 8 constructs ranged from 0.48 to 0.75. Factor loadings indicated that the individual items belonged to their respective constructs, as hypothesized. The predictive validity of the instrument was demonstrated by significant relationships between 5 of the 8 attitudinal constructs and an intent to treat to goal case study.
CONCLUSIONS: The HABIT physician survey is the first validated instrument covering a broad set of attitudes about the treatment of hyperlipidemia that are both theoretically and empirically linked to physician intent to treat to NCEP LDL-C goal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14687256      PMCID: PMC1494952          DOI: 10.1111/j.1525-1497.2003.30114.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  40 in total

1.  Why we need observational studies to evaluate the effectiveness of health care.

Authors:  N Black
Journal:  BMJ       Date:  1996-05-11

2.  Getting cardiologists interested in lipids.

Authors:  W C Roberts
Journal:  Am J Cardiol       Date:  1993-09-15       Impact factor: 2.778

Review 3.  Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

Authors:  S E Andrade; A M Walker; L K Gottlieb; N K Hollenberg; M A Testa; G M Saperia; R Platt
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

4.  Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs.

Authors:  G Simon; E Wagner; M Vonkorff
Journal:  J Clin Epidemiol       Date:  1995-03       Impact factor: 6.437

5.  Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease.

Authors:  C A Sueta; M Chowdhury; S J Boccuzzi; S C Smith; C M Alexander; A Londhe; A Lulla; R J Simpson
Journal:  Am J Cardiol       Date:  1999-05-01       Impact factor: 2.778

6.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

7.  Controversial beliefs about diabetes and its care.

Authors:  R M Anderson; M B Donnelly; W K Davis
Journal:  Diabetes Care       Date:  1992-07       Impact factor: 19.112

8.  Physician-based diet counseling for cholesterol reduction: current practices, determinants, and strategies for improvement.

Authors:  A S Ammerman; R F DeVellis; T S Carey; T C Keyserling; D S Strogatz; P S Haines; R J Simpson; D S Siscovick
Journal:  Prev Med       Date:  1993-01       Impact factor: 4.018

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1995-05-20       Impact factor: 79.321

View more
  3 in total

1.  Understanding and modifying physician behavior for prevention and management of cardiovascular disease.

Authors:  Paul A Heidenreich
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128

2.  Predictors of healthcare professionals' intention and behaviour to encourage physical activity in patients with cardiovascular risk factors.

Authors:  Barbara Sassen; Gerjo Kok; Luc Vanhees
Journal:  BMC Public Health       Date:  2011-04-19       Impact factor: 3.295

3.  Disparities in lipid management for African Americans and Caucasians with coronary artery disease: a national cross-sectional study.

Authors:  Mark W Massing; Kathleen A Foley; Lori Carter-Edwards; Carla A Sueta; Charles M Alexander; Ross J Simpson
Journal:  BMC Cardiovasc Disord       Date:  2004-08-18       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.